BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals, Inc.

Fairmount is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies.

Fairmount Funds

BioMarin is a global biotechnology company that develops and markets products to treat life-threatening genetic conditions. The company focuses on translating genetic discoveries into new medicines and collaborating with patient communities to improve care.

BioMarin

BioMarin Italia

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact.


Recruitment Fraud Alert Notice
 
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral.
 
In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.
 
If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit.

We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.


Our employees came together to assemble 180 back-to-school backpacks for students in our community last week. We put together backpacks for students in kindergarten through 12th grade, filling the backpacks with essentials for the school year. This event was sponsored by Life Science Cares Bay Area, an organization that works within the life science industry to fight poverty and inequalities. We donated the backpacks  to Ritter Center, a local organization that provides services to Marin County residents experiencing economic insecurities and homelessness. Thank you to our employees and to Life Science Cares Bay Area for making an impact in our community!

We’ve welcomed the first high school interns to BioMarin, in collaboration with Biotech Partners – a nonprofit organization dedicated to building biotech career skills among Bay Area youth. Enehemias and Paige are spending eight weeks this summer in our San Rafael labs, learning all about bench research from BioMarin scientists. Enehemias is spearheading the consolidation of our cell line storage databases, while Paige is conducting an energy efficiency analysis of our refrigeration systems. We’re proud to support these scientists-in-training and help cultivate the next generation of biotech leaders.

Today on National Intern Day, we are celebrating this year’s group of BioMarin interns, who we welcomed at the beginning of summer. Our skilled and innovative interns are working across a range of teams, including Finance, Legal, Technical Development, Quality, and Research. Their hard work is helping BioMarin address the unmet need for people living with genetic conditions. Thank you #BioMarininterns

Today we announced second-quarter 2024 results. Learn more: https://bit.ly/4dzceZN

For children living with achondroplasia, height is only one of the many factors to consider. To support children and families impacted by this condition, it’s crucial to apply a holistic approach that addresses all the unique challenges potentially faced.

There’s more to the conversation in achondroplasia than height alone. We’re committed to understanding the holistic experiences and challenges people living this condition face.

Metric
Company Name	BioMarin Pharmaceutical Inc.	Catalyst Pharmaceuticals, Inc.	Fairmount Funds
Symbol	BMRN	CPRX
MSH ID	COM:BIOMARIN	COM:CATALYSTPHARMA	COM:FAIRMOUNTFUNDS
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Financial Services & Finance
Industry	Biotechnology	Biotechnology	Investment Management
Country	US	US	US
Stage
Employee Count	3.40K	167
Website	biomarin.com	catalystpharma.com	fairmountfunds.com
LinkedIn	biomarin		fairmount-funds-management-llc
Founders

Metric
Market Cap	15.63B	1.83B
Enterprise Value
Monthly Web Traffic			88
Web Traffic Growth			-0.70
Valuation
Raised Capital

Metric
Revenue	2.42B	398.20M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.84B	313.67M
EBITDA	261.98M	119.95M
Operating Income	157.60M	86.81M
Net Income	167.65M	71.41M
EPS	0.87	0.67
Diluted EPS	0.87	0.63
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.79	0.85
Operating Profit Margin	0.09	0.22
EBITDA Margin	0.11	0.30
Net Profit Margin	0.10	0.18
Return on Equity	0.05	0.20
Return on Assets	0.04	0.15
Return on Capital Employed	0.04	0.22

COM:BIOMARIN

BioMarin

Last Close

63.45

22/11 21:00

Market Cap

15.63B

Beta: -

Volume Today

1.20M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	112.42	23.01
P/B Ratio	3.38	4.10
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.93	5.92
EV Multiple	2.98K	24.02

Metric
Days Sales Outstanding	90.44	50.34
Days Payables Outstanding	217.10	35.44
Days Inventory Outstanding	791.48	114.51
Operating Cycle	888.78	168.19
Cash Conversion Cycle	888.78	109.30
Asset Turnover	0.37	0.84

Metric
Operating Cash Flow	159.26M	143.60M
Free Cash Flow	51.65M	-54.92M
Cash Flow to Debt	0.30	58.30
Operating Cash Flow/Sales	0.13	0.45
Free Cash Flow Yield	0.00	0.03

Metric
Cash & Equivalents	755.13M	137.64M
Accounts Receivable	-190.44M	-43.08M
Inventory	1.11B	15.64M
Goodwill	196.20M
Debt to Capitalization	0.18	0.01
Debt to Assets	0.16	0.01
Current Ratio	2.54	3.32
Quick Ratio	6.42K	4.94

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.09	0.03
R&D to Revenue	0.31	0.27
SG&A to Revenue	0.19	0.12